Literature DB >> 517620

Combined trabeculectomy and cataract extraction.

G E Johns, W E Layden.   

Abstract

We performed combined trabeculectomy-cataract extraction in 37 eyes of 29 patients. Average follow-up was 23.7 months. Thirty-three (89.2%) of the 37 eyes were controlled with much improvement postoperatively. A total of 35 eyes (94.6%) were controlled postoperatively; 22 eyes (59.5%) required no medications postoperatively. No greater incidence of complications with the combined procedure from that expected with cataract extraction alone was evident, except for four flat or shallow chambers and four hyphemas, none of which appeared to have an adverse effect on the final outcome of the surgery. We believe that the combined trabeculectomy-cataract extraction is a valid and safe procedure, if not the procedure of choice, in our hands, for the patient with coexisting cataract and glaucoma, and the advantages of the greater pressure control with the single procedure outweight the small increase in the risks of the surgery.

Entities:  

Mesh:

Year:  1979        PMID: 517620     DOI: 10.1016/0002-9394(79)90401-x

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  4 in total

1.  Combined intracapsular cataract extraction and trabeculectomy with Severin five-loop posterior chamber intraocular lens.

Authors:  J A Coleiro
Journal:  Br J Ophthalmol       Date:  1986-09       Impact factor: 4.638

2.  Trabeculectomy and extracapsular cataract extraction with posterior chamber lens implantation: a long term study.

Authors:  R Fusco; P Guacci; G Ambrosio; M Murino
Journal:  Doc Ophthalmol       Date:  1990 Apr-Jul       Impact factor: 2.379

3.  Simultaneous trabeculectomy and cataract extraction.

Authors:  M Romem; I Isakow; Z Dolev
Journal:  Br J Ophthalmol       Date:  1982-04       Impact factor: 4.638

4.  Glaucoma triple procedure of extracapsular cataract extraction, posterior chamber lens implantation, and trabeculectomy.

Authors:  S P Percival
Journal:  Br J Ophthalmol       Date:  1985-02       Impact factor: 4.638

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.